SCO-101
Metastatic Colorectal Cancer (mCRC)
Key Facts
About Scandion Oncology
Scandion Oncology aimed to address the critical unmet need of cancer drug resistance by developing adjunctive, biomodulating therapies. Its lead asset, SCO-101, advanced to Phase 2 trials in metastatic colorectal cancer (mCRC) and Phase 1b in pancreatic cancer, targeting the ABCG2 efflux pump and UGT1A1 enzyme. Despite achieving clinical milestones, the company's strategic path to partnership or further funding was not realized, leading to a shareholder decision to liquidate the company in early 2025 and distribute remaining assets.
View full company profileAbout Scandion Oncology
Scandion Oncology aimed to address the critical unmet need of cancer drug resistance by developing adjunctive, biomodulating therapies. Its lead asset, SCO-101, advanced to Phase 2 trials in metastatic colorectal cancer (mCRC) and Phase 1b in pancreatic cancer, targeting the ABCG2 efflux pump and UGT1A1 enzyme. Despite achieving clinical milestones, the company's strategic path to partnership or further funding was not realized, leading to a shareholder decision to liquidate the company in early 2025 and distribute remaining assets.
View full company profileAbout Scandion Oncology
Scandion Oncology aimed to address the critical unmet need of cancer drug resistance by developing adjunctive, biomodulating therapies. Its lead asset, SCO-101, advanced to Phase 2 trials in metastatic colorectal cancer (mCRC) and Phase 1b in pancreatic cancer, targeting the ABCG2 efflux pump and UGT1A1 enzyme. Despite achieving clinical milestones, the company's strategic path to partnership or further funding was not realized, leading to a shareholder decision to liquidate the company in early 2025 and distribute remaining assets.
View full company profileTherapeutic Areas
Other Metastatic Colorectal Cancer (mCRC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Arfolitixorin | Isofol Medical | Phase Ib/II |